Pharvaris is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for rare diseases with unmet need, initially focused on angioedema and other bradykinin-mediated diseases. Co.'s first molecule, PHA121, is a small-molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema, or HAE. PHA121 has been observed to be a potent inhibitor in vitro as assessed using human recombinant bradykinin B2 receptors (150 pM); ex vivo as studied against endogenous bradykinin B2 receptors in a human umbilical vein model (350 pM); and in vivo in the human bradykinin-challenge model (170 pM). The PHVS stock yearly return is shown above.
The yearly return on the PHVS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PHVS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|